Y-MABS THERAPEUTICS, INC.

(YMAB)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Y-mAbs Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference

01/05/2022 | 09:01am EDT

NEW YORK, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that its Chief Executive Officer, Dr. Claus Moller, MD, Ph.D., will provide an overview and update on the Company's business at the virtual 40th Annual J.P. Morgan Healthcare Conference. The presentation will take place on Tuesday, January 11, 2022, at 9:00 AM Eastern Standard Time. The presentation can be accessed via a live audio webcast.

About Y-mAbs

Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. The Company has a broad and advanced product pipeline, including one FDA approved product, DANYELZA® (naxitamab-gqgk), which targets tumors that express GD2, and one pivotal-stage product candidate, omburtamab, which targets tumors that express B7-H3.

Forward-Looking Statements

Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about our business model and development, commercialization and product distribution plans; current and future clinical and pre-clinical studies and our research and development programs; expectations related to the timing of the initiation and completion of regulatory submissions; regulatory, marketing and reimbursement approvals; rate and degree of market acceptance and clinical utility as well as pricing and reimbursement levels; retaining and hiring key employees; our commercialization, marketing and manufacturing capabilities and strategy; our intellectual property position and strategy; additional product candidates and technologies; collaborations or strategic partnerships and the potential benefits thereof; expectations related to the use of our cash and cash equivalents, and the need for, timing and amount of any future financing transaction; our financial performance, including our estimates regarding revenues, expenses, capital expenditure requirements; developments relating to our competitors and our industry; and other statements that are not historical facts. Words such as ‘‘anticipate,’’ ‘‘believe,’’ “contemplate,” ‘‘continue,’’ ‘‘could,’’ ‘‘estimate,’’ ‘‘expect,’’ “hope,” ‘‘intend,’’ ‘‘may,’’ ‘‘might,’’ ‘‘plan,’’ ‘‘potential,’’ ‘‘predict,’’ ‘‘project,’’ ‘‘should,’’ ‘‘target,’’ “will”, ‘‘would’’ and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Our product candidates and related technologies are novel approaches to cancer treatment that present significant challenges. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including but not limited to: risks associated with our financial condition and need for additional capital; risks associated with our development work; cost and success of our product development activities and clinical trials; the risks of delay in the timing of our regulatory submissions or failure to receive approval of our drug candidates; the risks related to commercializing any approved pharmaceutical product including the rate and degree of market acceptance of our product candidates; development of our sales and marketing capabilities and risks associated with failure to obtain sufficient reimbursement for our products; the risks related to our dependence on third parties including for conduct of clinical testing and product manufacture; our inability to enter into partnerships; the risks related to government regulation; risks related to market approval, risks associated with protection of our intellectual property rights; risks related to employee matters and managing growth; risks related to our common stock, risks associated with the pandemic caused by the coronavirus known as COVID-19 and other risks and uncertainties affecting the Company including those described in the "Risk Factors" section included in our Annual Report on Form 10-K for the year ended December 31, 2020 filed with the SEC and in our other SEC filings. Any forward-looking statements contained in this press release speak only as of the date hereof, and the Company undertakes no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

DANYELZA and “Y-mAbs” are registered trademarks of Y-mAbs Therapeutics, Inc.

Contact:

Y-mAbs Therapeutics, Inc.
230 Park Avenue, Suite 3350
New York, NY 10169
USA

+1 646 885 8505

E-mail: info@ymabs.com


Primary Logo

Source: Y-mAbs Therapeutics, Inc

2022 GlobeNewswire, Inc., source Press Releases

All news about Y-MABS THERAPEUTICS, INC.
05/19Y-mAbs Therapeutics Appoints President Thomas Gad Interim CEO
MT
05/19Y-MABS THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
05/10Wedbush Adjusts Price Target for Y-mAbs Therapeutics to $21 From $28, Maintains Outperf..
MT
05/10TRANSCRIPT : Y-mAbs Therapeutics, Inc., Q1 2022 Earnings Call, May 10, 2022
CI
05/09Y-MABS THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition ..
AQ
05/09Y-mAbs Announces First Quarter Financial Results and Recent Corporate Developments
AQ
05/09Y-mAbs Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31..
CI
05/03Y-mAbs to Announce First Quarter 2022 Financial and Operating Results on May 9, 2022
AQ
04/28Wedbush Cuts Y-mAbs Therapeutics' Price Target to $28 From $36, Adjusting Nivatrotamab,..
MT
04/27Y MABS THERAPEUTICS : mAbs Announces Executive Management Changes and Provides 2022 Revenu..
PU
More news
Analyst Recommendations on Y-MABS THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2022 63,4 M - -
Net income 2022 -89,4 M - -
Net cash 2022 197 M - -
P/E ratio 2022 -4,96x
Yield 2022 -
Capitalization 438 M 438 M -
EV / Sales 2022 3,80x
EV / Sales 2023 2,88x
Nbr of Employees 148
Free-Float 87,7%
Chart Y-MABS THERAPEUTICS, INC.
Duration : Period :
Y-mAbs Therapeutics, Inc. Technical Analysis Chart | YMAB | US9842411095 | MarketScreener
Technical analysis trends Y-MABS THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 10,02 $
Average target price 27,83 $
Spread / Average Target 178%
EPS Revisions
Managers and Directors
Thomas Gad President & Chief Executive Officer
Bo Kruse CFO, Secretary. Treasurer & Executive VP
James Irvin Healy Chairman
Torben Lund-Hansen Chief Technology Officer & Senior Vice President
Steen Lisby Chief Scientific Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
Y-MABS THERAPEUTICS, INC.-38.19%438
GILEAD SCIENCES, INC.-12.08%80 075
REGENERON PHARMACEUTICALS, INC.4.69%71 235
VERTEX PHARMACEUTICALS17.76%66 136
WUXI APPTEC CO., LTD.-16.92%42 735
BIONTECH SE-36.77%39 612